TY - JOUR
T1 - Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated with Crizotinib
AU - Hida, Tomoyuki
AU - Dahlberg, Suzanne E.
AU - Lydon, Christine A.
AU - Hatabu, Hiroto
AU - Johnson, Bruce E.
AU - Awad, Mark M.
AU - Nishino, Mizuki
N1 - Funding Information:
Supported by research grant from Canon Medical Systems. S.E.D.: Consultancy for AstraZeneca. H.H.: Research funding from Canon Inc., Canon Medical Systems, and Konica-Minolta; Consultant to Toshiba Medical Systems. B.E.J.: research support: Canon Medical Systems and Novartis; Post Marketing Royalties for EGFR Mutation testing; Dana-Farber Cancer Institute. M.M.A.: Consultant to AstraZeneca, AbbVie, Boehringer-Ingelheim, Merck, Pfizer, Genentech. Research grant from the Conquer Cancer Foundation of the American Society of Clinical Oncology; and the International Association for the Study of Lung Cancer. M.N.: Consultant to Toshiba Medical Systems, WorldCare Clinical, Daiichi Sankyo; Research grant from Merck, Canon Medical Systems, AstraZeneca; Honorarium from Bayer and Roche. Funding support: research grant from Canon Medical Systems. The remaining authors declare no conflicts of interest.
Funding Information:
Supported by research grant from Canon Medical Systems. S.E.D.: Consultancy for AstraZeneca. H.H.: Research funding from Canon Inc., Canon Medical Systems, and Konica-Minolta; Con-sultant to Toshiba Medical Systems. B.E.J.: research support: Canon Medical Systems and Novartis; Post Marketing Royalties for EGFR Mutation testing; Dana-Farber Cancer Institute. M.M.A.: Con-sultant to AstraZeneca, AbbVie, Boehringer-Ingelheim, Merck, Pfizer, Genentech. Research grant from the Conquer Cancer Foun-dation of the American Society of Clinical Oncology; and the Inter-national Association for the Study of Lung Cancer. M.N.: Consultant to Toshiba Medical Systems, WorldCare Clinical, Daiichi Sankyo; Research grant from Merck, Canon Medical Systems, AstraZeneca; Honorarium from Bayer and Roche. Funding support: research grant from Canon Medical Systems. The remaining authors declare no conflicts of interest.
Publisher Copyright:
© 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Purpose:Targeted inhibition of anaplastic lymphoma kinase (ALK) has been widely used for the treatment of advanced non-small cell lung cancer (NSCLC) with ALK rearrangements. We performed tumor volume analysis of ALK-rearranged advanced NSCLC treated with crizotinib to identify an early predictive marker for prolonged survival.Materials and Methods:Cases of 42 patients with ALK-rearranged advanced NSCLC (16 men, 26 women; median age: 55.7 y) treated with crizotinib as their first ALK-directed therapy were retrospectively studied. Tumor volume measurements of dominant lung lesions were performed on baseline computed tomography and follow-up computed tomography at 8 weeks of therapy. The relationships between the 8-week volume change (%) and overall survival (OS) were investigated.Results:The 8-week tumor volume change ranged from -99.3% to 117.5% (median: -57.7%). Using the 25th percentile of the 8-week volume change of -74%, 11 patients with >74% volume decrease at 8 weeks had a significantly longer OS compared with 31 patients with ≤74% decrease (median OS: 92.0 vs. 22.8 mo; P=0.0048). In multivariable analyses using Cox proportional hazards models, the 8-week volume decrease of >74% was significantly associated with longer OS (hazard ratio=0.14, 95% confidence interval: 0.03-0.59; Cox P=0.008) after adjusting for tumor stage (stage IV vs. recurrent NSCLC, hazard ratio=5.6, 95% confidence interval: 1.29-24.3; P=0.02).Conclusions:The 8-week tumor volume decrease of >74% is significantly associated with longer OS in patients with ALK-rearranged NSCLC treated with crizotinib.
AB - Purpose:Targeted inhibition of anaplastic lymphoma kinase (ALK) has been widely used for the treatment of advanced non-small cell lung cancer (NSCLC) with ALK rearrangements. We performed tumor volume analysis of ALK-rearranged advanced NSCLC treated with crizotinib to identify an early predictive marker for prolonged survival.Materials and Methods:Cases of 42 patients with ALK-rearranged advanced NSCLC (16 men, 26 women; median age: 55.7 y) treated with crizotinib as their first ALK-directed therapy were retrospectively studied. Tumor volume measurements of dominant lung lesions were performed on baseline computed tomography and follow-up computed tomography at 8 weeks of therapy. The relationships between the 8-week volume change (%) and overall survival (OS) were investigated.Results:The 8-week tumor volume change ranged from -99.3% to 117.5% (median: -57.7%). Using the 25th percentile of the 8-week volume change of -74%, 11 patients with >74% volume decrease at 8 weeks had a significantly longer OS compared with 31 patients with ≤74% decrease (median OS: 92.0 vs. 22.8 mo; P=0.0048). In multivariable analyses using Cox proportional hazards models, the 8-week volume decrease of >74% was significantly associated with longer OS (hazard ratio=0.14, 95% confidence interval: 0.03-0.59; Cox P=0.008) after adjusting for tumor stage (stage IV vs. recurrent NSCLC, hazard ratio=5.6, 95% confidence interval: 1.29-24.3; P=0.02).Conclusions:The 8-week tumor volume decrease of >74% is significantly associated with longer OS in patients with ALK-rearranged NSCLC treated with crizotinib.
UR - http://www.scopus.com/inward/record.url?scp=85064281371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064281371&partnerID=8YFLogxK
U2 - 10.1097/RTI.0000000000000413
DO - 10.1097/RTI.0000000000000413
M3 - Article
C2 - 30985604
AN - SCOPUS:85064281371
SN - 0883-5993
VL - 35
SP - 101
EP - 107
JO - Journal of Thoracic Imaging
JF - Journal of Thoracic Imaging
IS - 2
ER -
